A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Latest Information Update: 27 May 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
Most Recent Events
- 20 May 2025 Planned End Date changed from 30 Apr 2025 to 15 Jul 2025.
- 20 May 2025 Planned primary completion date changed from 30 Apr 2025 to 15 Jul 2025.
- 06 Mar 2025 Planned End Date changed from 31 Dec 2025 to 30 Apr 2025.